Immuron Limited (IMRN)
NASDAQ: IMRN · IEX Real-Time Price · USD
2.640
+0.150 (6.02%)
At close: Apr 26, 2024, 4:00 PM
2.900
+0.260 (9.85%)
After-hours: Apr 26, 2024, 6:20 PM EDT
Immuron Revenue
Immuron had revenue of $2.43M in the twelve months ending December 31, 2023. In the fiscal year ending June 30, 2023, Immuron had annual revenue of $1.24M with 134.22% growth.
Revenue (ttm)
$2.43M
Revenue Growth
+134.22%
P/S Ratio
6.41
Revenue / Employee
$405,515
Employees
6
Market Cap
15.61M USD
Revenue Chart
* The company reports in AUD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2023 | 1.24M | 713.24K | 134.22% |
Jun 30, 2022 | 531.38K | 421.78K | 384.81% |
Jun 30, 2021 | 109.61K | -1.63M | -93.69% |
Jun 30, 2020 | 1.74M | 55.66K | 3.31% |
Jun 30, 2019 | 1.68M | 316.17K | 23.16% |
Jun 30, 2018 | 1.37M | 291.37K | 27.14% |
Jun 30, 2017 | 1.07M | 328.40K | 44.06% |
Jun 30, 2016 | 745.35K | -27.17K | -3.52% |
Jun 30, 2015 | 772.52K | -151.69K | -16.41% |
Jun 30, 2014 | 924.21K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Star Equity Holdings | 45.79M |
Pieris Pharmaceuticals | 42.81M |
BIMI International Medical | 5.85M |
NEXGEL | 4.09M |
Senti Biosciences | 2.56M |
Mainz Biomed B.V. | 895.48K |
BioSig Technologies | 18.00K |
IMRN News
- 12 days ago - Immuron to host Live Virtual Event - GlobeNewsWire
- 17 days ago - Immuron Travelan® sales continued strong growth - GlobeNewsWire
- 7 weeks ago - Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US - GlobeNewsWire
- 2 months ago - Immuron Presentation Australian Biologics Festival 2024 - GlobeNewsWire
- 2 months ago - Immuron achieves record Travelan® sales - GlobeNewsWire
- 2 months ago - Immuron CEO, Steven Lydeamore Investor Webinar Presentation - GlobeNewsWire
- 3 months ago - Immuron achieves record half yearly Travelan® sales - GlobeNewsWire
- 4 months ago - Immuron Clinical Trials Update - GlobeNewsWire